No Data
Press Release: Teva Announces Strong Financial Results for the Third Quarter of 2024, Led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook Including on Revenues, Adjusted EBITDA and Non-GAAP EPS
Teva Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Earnings and Raised Its Guidance.
Earnings Flash (TEVA) TEVA PHARMACEUTICAL INDUSTRIES Reports Q3 Revenue $4.33B
Teva Forecasts 2024 Adjusted EPS Of $2.40-$2.50 Versus Prior Guidance Of $2.30-$2.50 And Consensus Of $2.45
Earnings Flash (TEVA) TEVA PHARMACEUTICAL INDUSTRIES Posts Q3 EPS $0.69
Teva Pharmaceuticals Raises FY24 View To Rev $16.1B-$16.5B >TEVA